HTG Molecular Diagnostics Introduces HTG EdgeSeq PATH Assay to Launch in Second Quarter 2017
May 04 2017 - 8:30AM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of
instruments, reagents and services for molecular profiling
applications, announced that its new HTG EdgeSeq PATH Assay is
expected to be available for research uses by the end of the second
quarter of 2017. The HTG EdgeSeq PATH Assay (previously referred to
as project Mercury) has been designed for retrospective gene
expression profiling to complement traditional immunohistochemistry
(IHC) testing by allowing investigators to assess mRNA expression
of large numbers of biomarkers when formalin-fixed,
paraffin-embedded sample availability is limited. The assay is
designed to detect up to 470 mRNA targets, typically assessed by
IHC.
“We believe a multiplexed, quantitative assay that profiles IHC
biomarkers in small samples is an important research-use complement
to traditional IHC, and are excited to rapidly expand our available
menu following the recent launch of our HTG EdgeSeq EGFR, KRAS and
BRAF Mutation Assay as a research use only (RUO) service offering,”
stated TJ Johnson, President and Chief Executive Officer of
HTG.
“Our commercial team is now actively engaged with early adopters
and we plan to have the HTG EdgeSeq PATH Assay available for
shipment by the end of this quarter,” stated Mike Hrubiak, HTG’s
Vice President, Marketing.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular
Diagnostics (HTG) is to empower precision medicine at the local
level. In 2013 the company commercialized its first instrument
platform and a portfolio of RNA assays that leveraged HTG's
original proprietary nuclease protection chemistry. Continuous
improvement led to the 2014 launch of the company’s HTG EdgeSeq
product line, which automates sample and targeted library
preparation for next-generation sequencing. Additional information
is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the expected availability of,
and benefits to be derived from, our new HTG EdgeSeq PATH Assay.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements, though not all
forward-looking statements necessarily contain these identifying
words. These forward-looking statements are based upon management's
current expectations, are subject to known and unknown risks, and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties,
including, without limitation, the risk that we may not
commercialize the HTG EdgeSeq PATH Assay when expected, or at all,
the risk that the HTG EdgeSeq PATH Assay may not provide the
anticipated benefits to our customers, risks associated with the
process of developing and commercializing diagnostic products, our
ability to achieve and sustain sufficient market acceptance, and
the capabilities of our product and service solutions to keep pace
with rapidly changing technology and customer requirements. These
and other factors are described in greater detail in our filings
with the Securities and Exchange Commission, including without
limitation our Annual Report on Form 10-K for the year ended
December 31, 2016. All forward-looking statements contained in this
press release speak only as of the date on which they were made,
and we undertake no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2023 to Apr 2024